The leukemogenic BCR-ABL fusion protein activates multiple signal transduction pathways which, in turn, may affect the expression of genes implicated in the pathogenesis of CML [14]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.